|
|
Article: Roche Dramatically Reduces Cost of Combination Therapy for Millions of Americans Chronically Infected with Hepatitis C; Copegus, used in combination with Pegasys, rolls ribavirin cost per milligram back 43 percent to 1998 price.
- Article from:
- PR Newswire
- Article date:
- January 13, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NUTLEY, N.J. -- NUTLEY, N.J., Jan. 13 /PRNewswire/ -- Roche today announced that Copegus(TM) (ribavirin, USP), the medication used in combination with Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis C, is being introduced with a list price or wholesale acquisition cost that is 43 percent less per milligram than the other available brand of ribavirin. Copegus will be available in U.S. pharmacies beginning the week of January 13. The list price or wholesale acquisition cost for Copegus is $5.06 per 200mg tablet.
Pegasys and Copegus combination therapy was approved by the U.S. Food and Drug Administration (F.D.A.) on December 3, 2002, for ...